Cargando…
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma
Kinase fusions have been identified in a growing subset of sarcomas, but a lack of preclinical models has impeded their functional analysis as therapeutic targets in the sarcoma setting. In this study, we generated models of sarcomas bearing kinase fusions and assessed their response to molecularly...
Autores principales: | Odintsov, Igor, Ortiz, Michael V., Khodos, Inna, Mattar, Marissa S., Lui, Allan J.W., Kohsaka, Shinji, de Stanchina, Elisa, Bender, Julia L. Glade, Ladanyi, Marc, Somwar, Romel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930606/ https://www.ncbi.nlm.nih.gov/pubmed/35074756 http://dx.doi.org/10.1158/0008-5472.CAN-21-1397 |
Ejemplares similares
-
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
por: Somwar, Romel, et al.
Publicado: (2020) -
LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID
por: Offin, Michael, et al.
Publicado: (2019) -
RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021) -
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022) -
A blast from the past: ROS1 on the brain
por: Odintsov, Igor, et al.
Publicado: (2019)